Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399651 | 1.00 | OPRL1 (0.54) | OPRL1TFPIOPRM1OPRD1KISS1R | |
| SCHEMBL31243859 | 0.89 | OPRD1 (0.58) | OPRL1TFPIOPRM1OPRD1 | |
| SCHEMBL31243865 | 0.89 | OPRD1 (0.58) | OPRL1TFPIOPRM1OPRD1 | |
| SCHEMBL31480024 | 0.89 | OPRL1 (0.63) | OPRL1TFPIOPRM1OPRD1 | |
| SCHEMBL29408578 | 0.89 | ERAP2 (0.53) | — | |
| SCHEMBL29575653 | 0.87 | TFPI (0.57) | OPRL1TFPI | |
| SCHEMBL13811868 | 0.87 | TFPI (0.60) | OPRL1TFPIKISS1R | |
| SCHEMBL31243908 | 0.86 | OPRD1 (0.55) | OPRL1TFPIOPRM1OPRD1 | |
| SCHEMBL10747004 | 0.86 | OPRL1 (0.59) | OPRL1TFPI | |
| SCHEMBL10746970 | 0.86 | OPRL1 (0.59) | OPRL1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| CN-1189166-C | FC receptor modulators and uses thereof | ILEXUS PTY LTD (AU) | 2005-02-16 | — | — | CN | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| CN-1323203-A | FC receptor modulators and uses thereof | ILEXUS PTY LTD (AU) | 2001-11-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | OPRL1 211/4885TFPI 1232/4885OPRM1 1097/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | OPRL1 318/4885TFPI 348/4885OPRM1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.